Copyright Reports & Markets. All rights reserved.

Global Gliclazide Sustained-release Tablet Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Gliclazide Sustained-release Tablet Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 30mg
    • 1.3.3 60mg
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Gliclazide Sustained-release Tablet Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Other
  • 1.5 Global Gliclazide Sustained-release Tablet Market Size & Forecast
    • 1.5.1 Global Gliclazide Sustained-release Tablet Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Gliclazide Sustained-release Tablet Sales Quantity (2021-2032)
    • 1.5.3 Global Gliclazide Sustained-release Tablet Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Servier Laboratories
    • 2.1.1 Servier Laboratories Details
    • 2.1.2 Servier Laboratories Major Business
    • 2.1.3 Servier Laboratories Gliclazide Sustained-release Tablet Product and Services
    • 2.1.4 Servier Laboratories Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Servier Laboratories Recent Developments/Updates
  • 2.2 Torrent Pharmaceuticals
    • 2.2.1 Torrent Pharmaceuticals Details
    • 2.2.2 Torrent Pharmaceuticals Major Business
    • 2.2.3 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Product and Services
    • 2.2.4 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Torrent Pharmaceuticals Recent Developments/Updates
  • 2.3 Aurobindo Pharma
    • 2.3.1 Aurobindo Pharma Details
    • 2.3.2 Aurobindo Pharma Major Business
    • 2.3.3 Aurobindo Pharma Gliclazide Sustained-release Tablet Product and Services
    • 2.3.4 Aurobindo Pharma Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Aurobindo Pharma Recent Developments/Updates
  • 2.4 Teva
    • 2.4.1 Teva Details
    • 2.4.2 Teva Major Business
    • 2.4.3 Teva Gliclazide Sustained-release Tablet Product and Services
    • 2.4.4 Teva Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Teva Recent Developments/Updates
  • 2.5 Zydus Cadila Healthcare
    • 2.5.1 Zydus Cadila Healthcare Details
    • 2.5.2 Zydus Cadila Healthcare Major Business
    • 2.5.3 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Product and Services
    • 2.5.4 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Zydus Cadila Healthcare Recent Developments/Updates
  • 2.6 Sanofi S.A.
    • 2.6.1 Sanofi S.A. Details
    • 2.6.2 Sanofi S.A. Major Business
    • 2.6.3 Sanofi S.A. Gliclazide Sustained-release Tablet Product and Services
    • 2.6.4 Sanofi S.A. Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sanofi S.A. Recent Developments/Updates
  • 2.7 Mylan Pharmaceuticals
    • 2.7.1 Mylan Pharmaceuticals Details
    • 2.7.2 Mylan Pharmaceuticals Major Business
    • 2.7.3 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Product and Services
    • 2.7.4 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Mylan Pharmaceuticals Recent Developments/Updates
  • 2.8 Accord Healthcare
    • 2.8.1 Accord Healthcare Details
    • 2.8.2 Accord Healthcare Major Business
    • 2.8.3 Accord Healthcare Gliclazide Sustained-release Tablet Product and Services
    • 2.8.4 Accord Healthcare Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Accord Healthcare Recent Developments/Updates
  • 2.9 Lukang Jituan Saite Yaoye
    • 2.9.1 Lukang Jituan Saite Yaoye Details
    • 2.9.2 Lukang Jituan Saite Yaoye Major Business
    • 2.9.3 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Product and Services
    • 2.9.4 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Lukang Jituan Saite Yaoye Recent Developments/Updates
  • 2.10 Shijiazhuang SIYAO
    • 2.10.1 Shijiazhuang SIYAO Details
    • 2.10.2 Shijiazhuang SIYAO Major Business
    • 2.10.3 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Product and Services
    • 2.10.4 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Shijiazhuang SIYAO Recent Developments/Updates
  • 2.11 Yiling Pharmaceutical
    • 2.11.1 Yiling Pharmaceutical Details
    • 2.11.2 Yiling Pharmaceutical Major Business
    • 2.11.3 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Product and Services
    • 2.11.4 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Yiling Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Gliclazide Sustained-release Tablet by Manufacturer

  • 3.1 Global Gliclazide Sustained-release Tablet Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Gliclazide Sustained-release Tablet Revenue by Manufacturer (2021-2026)
  • 3.3 Global Gliclazide Sustained-release Tablet Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Gliclazide Sustained-release Tablet by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Gliclazide Sustained-release Tablet Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Gliclazide Sustained-release Tablet Manufacturer Market Share in 2025
  • 3.5 Gliclazide Sustained-release Tablet Market: Overall Company Footprint Analysis
    • 3.5.1 Gliclazide Sustained-release Tablet Market: Region Footprint
    • 3.5.2 Gliclazide Sustained-release Tablet Market: Company Product Type Footprint
    • 3.5.3 Gliclazide Sustained-release Tablet Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Gliclazide Sustained-release Tablet Market Size by Region
    • 4.1.1 Global Gliclazide Sustained-release Tablet Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Gliclazide Sustained-release Tablet Consumption Value by Region (2021-2032)
    • 4.1.3 Global Gliclazide Sustained-release Tablet Average Price by Region (2021-2032)
  • 4.2 North America Gliclazide Sustained-release Tablet Consumption Value (2021-2032)
  • 4.3 Europe Gliclazide Sustained-release Tablet Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Gliclazide Sustained-release Tablet Consumption Value (2021-2032)
  • 4.5 South America Gliclazide Sustained-release Tablet Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Gliclazide Sustained-release Tablet Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Gliclazide Sustained-release Tablet Sales Quantity by Type (2021-2032)
  • 5.2 Global Gliclazide Sustained-release Tablet Consumption Value by Type (2021-2032)
  • 5.3 Global Gliclazide Sustained-release Tablet Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Gliclazide Sustained-release Tablet Sales Quantity by Application (2021-2032)
  • 6.2 Global Gliclazide Sustained-release Tablet Consumption Value by Application (2021-2032)
  • 6.3 Global Gliclazide Sustained-release Tablet Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Gliclazide Sustained-release Tablet Sales Quantity by Type (2021-2032)
  • 7.2 North America Gliclazide Sustained-release Tablet Sales Quantity by Application (2021-2032)
  • 7.3 North America Gliclazide Sustained-release Tablet Market Size by Country
    • 7.3.1 North America Gliclazide Sustained-release Tablet Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Gliclazide Sustained-release Tablet Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Gliclazide Sustained-release Tablet Sales Quantity by Type (2021-2032)
  • 8.2 Europe Gliclazide Sustained-release Tablet Sales Quantity by Application (2021-2032)
  • 8.3 Europe Gliclazide Sustained-release Tablet Market Size by Country
    • 8.3.1 Europe Gliclazide Sustained-release Tablet Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Gliclazide Sustained-release Tablet Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Gliclazide Sustained-release Tablet Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Gliclazide Sustained-release Tablet Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Gliclazide Sustained-release Tablet Market Size by Region
    • 9.3.1 Asia-Pacific Gliclazide Sustained-release Tablet Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Gliclazide Sustained-release Tablet Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Gliclazide Sustained-release Tablet Sales Quantity by Type (2021-2032)
  • 10.2 South America Gliclazide Sustained-release Tablet Sales Quantity by Application (2021-2032)
  • 10.3 South America Gliclazide Sustained-release Tablet Market Size by Country
    • 10.3.1 South America Gliclazide Sustained-release Tablet Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Gliclazide Sustained-release Tablet Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Gliclazide Sustained-release Tablet Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Gliclazide Sustained-release Tablet Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Gliclazide Sustained-release Tablet Market Size by Country
    • 11.3.1 Middle East & Africa Gliclazide Sustained-release Tablet Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Gliclazide Sustained-release Tablet Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Gliclazide Sustained-release Tablet Market Drivers
  • 12.2 Gliclazide Sustained-release Tablet Market Restraints
  • 12.3 Gliclazide Sustained-release Tablet Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Gliclazide Sustained-release Tablet and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Gliclazide Sustained-release Tablet
  • 13.3 Gliclazide Sustained-release Tablet Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Gliclazide Sustained-release Tablet Typical Distributors
  • 14.3 Gliclazide Sustained-release Tablet Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Gliclazide Sustained-release Tablet market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Gliclazide is an oral antidiabetic medication used to treat type 2 diabetes mellitus. It belongs to the class of sulfonylurea drugs, which work by stimulating the pancreas to produce more insulin and increasing the body"s sensitivity to insulin. Gliclazide sustained-release tablets, often referred to as extended-release or controlled-release tablets, are a specific formulation of this medication.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Gliclazide Sustained-release Tablet market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Gliclazide Sustained-release Tablet market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Gliclazide Sustained-release Tablet market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Gliclazide Sustained-release Tablet market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Gliclazide Sustained-release Tablet market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Gliclazide Sustained-release Tablet
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Gliclazide Sustained-release Tablet market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Servier Laboratories, Torrent Pharmaceuticals, Aurobindo Pharma, Teva, Zydus Cadila Healthcare, Sanofi S.A., Mylan Pharmaceuticals, Accord Healthcare, Lukang Jituan Saite Yaoye, Shijiazhuang SIYAO, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Gliclazide Sustained-release Tablet market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    30mg
    60mg
    Other
    Market segment by Application
    Hospital
    Clinic
    Other
    Major players covered
    Servier Laboratories
    Torrent Pharmaceuticals
    Aurobindo Pharma
    Teva
    Zydus Cadila Healthcare
    Sanofi S.A.
    Mylan Pharmaceuticals
    Accord Healthcare
    Lukang Jituan Saite Yaoye
    Shijiazhuang SIYAO
    Yiling Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Gliclazide Sustained-release Tablet product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Gliclazide Sustained-release Tablet, with price, sales quantity, revenue, and global market share of Gliclazide Sustained-release Tablet from 2021 to 2026.
    Chapter 3, the Gliclazide Sustained-release Tablet competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Gliclazide Sustained-release Tablet breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Gliclazide Sustained-release Tablet market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Gliclazide Sustained-release Tablet.
    Chapter 14 and 15, to describe Gliclazide Sustained-release Tablet sales channel, distributors, customers, research findings and conclusion.

    Buy now